Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).
Methods:
We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting b 2 -agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 mg with twice-daily long-acting b 2 -agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 mg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints.
Measurements and Main Results:
We compared treatment efficacy according to blood eosinophil percentage (,2% and >2%, ,3% and >3%, and ,5% and >5%) and absolute blood eosinophil count (,150 cells/ml, 150 to ,300 cells/ml, and >300 cells/ml). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the ,2%, >2%, ,3%, ,5%, and ,150 cells/ml subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the ,2% and >2% subgroups.
Conclusions: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.
A range of pharmacological treatments for chronic obstructive pulmonary disease (COPD) reduce exacerbation risk, including long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and longacting b 2 -agonists [LABAs] , alone or in combination) and inhaled corticosteroids (ICS) in combination with LABAs (1) (2) (3) (4) (5) (6) (7) (8) (9) .
A LABA/LAMA combination is recommended as initial therapy by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients with a high symptom level who are at increased risk for exacerbation, determined by their exacerbation history (GOLD D) (9) . LABA/ICS are only recommended as an alternative treatment in GOLD D patients who develop further exacerbations after initial LABA/LAMA therapy, or with a history and/or findings suggestive of asthma-COPD overlap (9) . These recommendations are largely based on the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which demonstrated the superiority of LABA/LAMA indacaterol/glycopyrronium (IND/GLY) versus the LABA/ICS salmeterol/fluticasone propionate combination (SFC) in exacerbation prevention in patients with one or more exacerbations in the previous year (10) . There are safety concerns associated with ICS use (11) (12) (13) (14) ; therefore, the identification of patients in whom ICS treatment would be effective is needed to reduce unnecessary exposure of patients to risks. Furthermore, identifying optimal responders to each treatment strategy is necessary for treatment personalization in COPD (15) .
Evidence has emerged suggesting that sputum eosinophils may predict responsiveness to ICS (16) (17) (18) (19) . However, results are conflicting, and there are technical challenges associated with assessing sputum samples in clinical practice (16, 17, 20, 21) . Several studies have suggested that sputum eosinophil count may correlate with peripheral blood eosinophil count (18, 22, 23) , leading many to propose blood eosinophils as a potential biomarker for the relative efficacy of ICS in exacerbation prevention. Several blood eosinophil cutoffs have been studied in post hoc analyses, which suggested that blood eosinophils could predict the efficacy of LABA/ICS in preventing exacerbations relative to bronchodilator monotherapy or placebo (24) (25) (26) (27) . Although currently under debate, GOLD suggests "high" blood eosinophils may be considered a parameter to support ICS use in GOLD D patients (9) .
Our objective was to examine the relationship between baseline blood eosinophils and the rate of exacerbations with IND/GLY compared with SFC through analysis of data from FLAME (10) . This analysis is the first prospective evaluation of blood eosinophils as a predictor of response to an ICS-containing regimen versus a dual bronchodilator, supplemented and supported by post hoc analyses. Some of the results of this study have been reported previously in the form of a manuscript and an abstract (10, 28) .
Methods

Study Design
The FLAME study design has been reported previously (10) . Briefly, FLAME (NCT01782326) was a 52-week, multicenter, double-blind, active-controlled study that evaluated the efficacy of IND/GLY 110/50 mg once daily (Novartis Pharma AG, Basel, Switzerland) compared with SFC 50/500 mg twice daily (GlaxoSmithKline plc, London, United Kingdom) in exacerbation prevention in patients with moderate to very severe airflow limitation and at least one documented exacerbation in the previous year.
The primary objective of FLAME was to demonstrate the noninferiority of IND/GLY to SFC with regard to the rate of all COPD exacerbations (mild/moderate/severe) at 52 weeks. Superiority of IND/GLY versus SFC for the same endpoint (if noninferiority was met) was an important secondary objective. Other secondary objectives included time to first exacerbation (all) and rate and time to first moderate or severe exacerbation, health status (St. George's Respiratory Questionnaire for COPD [SGRQ-C]), trough forced expiratory volume in 1 second (FEV 1 ), trough forced vital capacity (FVC), and rescue medication. Safety endpoints were also assessed.
Patients
Eligible patients had a post-bronchodilator FEV 1 >25% and ,60% predicted, a postbronchodilator FEV 1 /FVC ,0.70, and one or more documented COPD exacerbation (requiring treatment with systemic corticosteroids and/or antibiotics) in the previous 12 months. Exclusion criteria included any history of asthma and a blood eosinophil count .600 cells/ml. Further inclusion and exclusion criteria have been described previously (10) .
Assessments and Variables
Exacerbations were defined as a worsening of symptoms according to modified Anthonisen criteria (29 Figure E1 ).
Statistical Analyses
Details on the statistical analysis of efficacy and safety endpoints (Table E1) can be found in the online supplement.
Blood eosinophil cutoffs were applied to measurements at the start of the treatment period according to percentage of total white blood cell count (,2% and >2%, ,3% and >3%, and ,5% and >5%) and absolute eosinophil count (,150 cells/ml, 150 to ,300 cells/ml, and >300 cells/ml). These correspond to cutoffs reported and discussed most often in the literature. Demographic and safety data were analyzed using only the ,2% and >2% cutoffs, as conducted in earlier, post hoc analyses (24, 27) . No substantial differences were noted compared with the analysis of the total study population; therefore, no further data cuts were analyzed. Analysis of exacerbation rate by blood eosinophils was prespecified, as was the time to first exacerbation for all exacerbations (at cutoffs of ,150 cells/ml, 150 to ,300 cells/ml, and >300 cells/ml). The remaining analyses were conducted post hoc.
Results
Patients
Patients excluded from FLAME because of blood eosinophils >600 cells/ml. Between study entry and randomization, 163 (3.1%) patients failed screening (at the run-in visit) because of a blood eosinophil count .600 cells/ml. Subjects could fail screening because of multiple inclusion or exclusion criteria (10 (Table E2 ). Baseline absolute cell count was also similar in the IND/GLY and SFC treatment groups (median, 180 cells/ml; IQR, 110-280 cells/ml for both; Table E2 ). Patients with >2%, >3%, and >5% blood eosinophils represented 60.9%, 36.9%, and 12.5% of the study population, respectively (Table E3 ). Distribution of baseline blood eosinophils was similar in the two treatment groups (Figures E2A and E2B).
Patients with blood eosinophils ,2% and >2% were relatively similar with regard to demographic and disease characteristics ( Table 1 ). Of note, there were no differences in baseline lung function (FEV 1 % predicted), bronchodilator reversibility, or the proportion of GOLD D patients (GOLD 2015 criteria) in each subgroup. Slightly more patients in the blood eosinophils >2% subgroup had two or more exacerbations in the previous year compared with in the ,2% subgroup (20.9% vs. 16.9%, respectively).
Exacerbations
Rate of exacerbations with increasing baseline blood eosinophils. In the overall study population, there was no evidence for an increase in the rate of moderate or severe exacerbations with increasing baseline eosinophils (percentage change in exacerbation rate per unit increase in eosinophils: 7% [95% CI, 220% to 42%]; P = 0.653).
Rate of exacerbations by treatment and baseline blood eosinophils. As published previously (10) Figures 1A and 1B) . Notably, the subgroups reduced in size as blood eosinophil percentage increased (,3%: n = 2,078; >3%: n = 1,220; ,5%: n = 2,886; >5%: n = 412).
IND/GLY was also significantly superior to SFC for reductions in the rate of moderate or severe exacerbations and all exacerbations in the ,150 cells/ml subgroup (both P , 0.001); the reductions observed in the 150 to ,300 cells/ml and >300 cells/ml subgroups were not statistically significant ( Figures 1A and 1B ). There were fewer patients in the >300 cells/ml subgroup (n = 735) compared with the ,150 cells/ml (n = 1,277) and 150 to ,300 cells/ml (n = 1,286) subgroups. The RRs approached 1 as blood eosinophil cutoff increased ( Figures 1A and 1B) . Figures  2A and 2B ). In the >3% and >5% subgroups, the risk reduction with IND/GLY compared with SFC did not reach statistical significance for moderate or severe exacerbations and for all exacerbations (Figures 2A and 2B ). Using absolute blood eosinophil count cutoffs, IND/GLY was significantly superior to SFC for reductions in the risk for moderate or severe exacerbations and for all exacerbations in the ,150 cells/ml subgroup (both P , 0.001). The risk reduction for moderate or severe exacerbations with IND/GLY compared with SFC reached significance in the 150 to ,300 cells/ml subgroup but not in the >300 cells/ml subgroup (Figure 2A ).
Other Secondary Endpoints
IND/GLY significantly improved mean SGRQ-C score at Week 52 (Table E4) and significantly improved the proportion of patients achieving a 4-unit change in SGRQ-C total score at Week 52 compared with SFC in the ,2% subgroup (Table E4) .
IND/GLY significantly improved trough FEV 1 and FVC at Week 52 (Table  E5) and significantly reduced rescue medication use over the course of 52 weeks compared with SFC in both the ,2% and >2% subgroups (Table E6) .
Similar trends in health status, lung function, and rescue medication outcomes were observed in the ,150 cells/ml, >150 cells/ml, ,300 cells/ml, and >300 cells/ml subgroups compared with those observed in the ,2% and >2% subgroups (Tables E4-E6 ).
Safety
The incidence of adverse events and serious adverse events was similar between both treatment groups and between the ,2% and >2% subgroups. The rate of pneumonia was low overall, but it was higher in the SFC group than the IND/GLY group in both the ,2% and >2% subgroups (5.5% vs. 4.1% in the ,2% subgroup; 4.3% vs. 2.6% in the >2% subgroup; Table E7 ). The number of adjudicated major adverse cardiac events and/or cardiovascular deaths was similar between both treatment groups (Table E8) .
Change in Blood Eosinophils over Time
Change in blood eosinophils between run-in visit and baseline. There was a slight increase in mean blood eosinophils in the total population between the run-in visit and baseline (0.3%; 21 cells/ml), with a smaller change observed in median blood eosinophils (0.1%; 0 cells/ml) (Table E9) . Prior ICS use did not affect the change in blood eosinophils.
Change in blood eosinophils between baseline and Weeks 26 and 52. There were minimal changes in mean blood eosinophils from baseline to Weeks 26 and 52 in the IND/GLY group (20.06% and 20.05%, respectively; 23 cells/ml and 23 cells/ml, respectively; Table 2 ). In the SFC group, there were small reductions in mean blood eosinophils from baseline to Weeks 26 and 52 (20.29% and 20.37%, respectively; 219 cells/ml and 225 cells/ml, respectively; Table 2 ). The between-group difference Hazard ratios (95% CI) and estimated time to first moderate or severe chronic obstructive pulmonary disease exacerbation by blood eosinophil cutoff. *Because less than 50% of patients in the indacaterol-glycopyrronium group had an exacerbation, the time by which at least 25% of patients had a first moderate or severe exacerbation was calculated instead of the median time. (B) Hazard ratios and estimated time to first mild, moderate, or severe (all) chronic obstructive pulmonary disease exacerbation by blood eosinophil cutoff. CI = confidence interval; GLY = glycopyrronium; IND = indacaterol; SFC = salmeterol/fluticasone propionate combination.
in change from baseline in mean blood eosinophils was significant using both percentage and absolute blood eosinophil count ( Table 2) .
Discussion
Finding an accessible, easy-to-measure biomarker for patients who may benefit from ICS is important to avoid unnecessary exposure to ICS-associated risks (11) (12) (13) (14) . One such biomarker could be blood eosinophils, with post hoc analyses suggesting >2% may be a suitable cutoff for relative ICS efficacy (24, 25, 27) . However, these retrospective analyses examined only the relative efficacy of LABA/ICS versus bronchodilator monotherapy or placebo (24) (25) (26) (27) . FLAME was the first trial to prospectively study the influence of blood eosinophils on LABA/ICS efficacy versus a LABA/LAMA. We found that IND/GLY was significantly superior to SFC for exacerbation prevention in patients, independent of blood eosinophil count above or below 2%. There were minimal differences in the RRs for moderate or severe exacerbations among the ,2%, ,3%, and ,5% subgroups (RR, 0.80, 0.81, and 0.81, respectively). Although the RR in the >3% subgroup still favored IND/GLY, the difference did not reach statistical significance. At a cutoff of >5%, the two treatments appeared approximately similar (RR, 0.94). This suggests that any ICS benefit was observed primarily in those with the highest blood eosinophil levels. However, it is notable that at no cutoff was SFC statistically superior to IND/GLY for exacerbation rate. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing baseline blood eosinophils, which differs from previous analyses (30, 31) .
The results of our analysis contrast with earlier findings from Pascoe and colleagues, who found that patients with >2% blood eosinophils gained a greater benefit from fluticasone furoate/vilanterol versus vilanterol monotherapy compared with patients with blood eosinophils ,2% (24) . A cutoff of >2% is associated with a number of limitations. First, blood eosinophil percentage levels are variable, and blood eosinophil levels may oscillate above and below 2% (24, 32) . Second, blood eosinophil percentage is relative to patients' white blood cell count; therefore, absolute blood eosinophil count may in fact be within the normal range, or even low at 2% if white blood cell count is low.
In another post hoc study, Siddiqui and colleagues found that patients with blood eosinophils >279.8 cells/ml gained a greater benefit from beclomethasone/ formoterol versus formoterol monotherapy compared with patients with lower blood eosinophils (26) .
Although high eosinophil counts may identify patients more likely to respond to ICS relative to placebo or LABA monotherapy, such markers may be irrelevant when comparing ICS with a more effective dual bronchodilator regimen, particularly when considering the efficacy of LAMAs in reducing exacerbations (2, (33) (34) (35) (36) (37) and reductions in exacerbation rate with a LAMA plus a LABA relative to LABA monotherapy (4).
Our protocol excluded patients with a history of asthma and patients with a blood eosinophil count .600 cells/ml at the run-in visit (a routine exclusion criterion throughout the IND/GLY clinical development program, predating discussions concerning blood eosinophils as a biomarker). The results of analyses from other studies may have been skewed by the inclusion of patients with an asthmatic component to their obstructive airways disease or a small subset of patients with higher eosinophil counts, associated with Th2-driven airways inflammation. However, reversibility level in FLAME was similar to other studies (4, 10, (38) (39) (40) , and only 3.1% of screened patients in FLAME were excluded on the basis of the upper blood eosinophil criterion, a benchmark we feel is reflective of the majority of patients with moderate to very severe airflow limitation and an exacerbation history. Thus, although we cannot exclude a benefit of SFC over IND/GLY in patients with extremely high blood eosinophil counts, the FLAME data are applicable to approximately 97% of patients with COPD. Notably, in the majority of analyses (including FLAME), 54-70% of patients had blood eosinophils >2% (24, 25, 27, 41) .
Blood eosinophils may still serve a purpose in identifying patients potentially at risk after withdrawal of ICS from their triple regimen. In analyses of data from WISDOM, withdrawal of ICS had a more deleterious effect in patients with blood eosinophils >4% or >400 cells/ml than in those with lower eosinophil counts (42) . Further analyses indicated that ICS withdrawal only resulted in an increased exacerbation rate in patients with both a high blood eosinophil count (>300 cells/ml and >400 cells/ml) and a history of two or more exacerbations, a subset representing less than 4% of the WISDOM population (43, 44) . Blood eosinophils may also help identify patients who would benefit from the addition of ICS to a dual bronchodilator. This hypothesis will be specifically tested as a prespecified secondary endpoint in the IMPACT trial, which will compare triple therapy with a LABA/LAMA and a LABA/ICS (45) . Mean blood eosinophils increased slightly between the run-in visit and baseline in FLAME, possibly because of artificial "capping" of variability in blood eosinophils at the run-in visit (but not baseline) to a maximum of 600 cells/ml. This hypothesis is supported by the fact that prior ICS use did not affect mean change. Blood eosinophil count decreased slightly over the study in those receiving SFC. This effect, combined with a greater lowering of urine cortisol observed with SFC versus IND/GLY (10), likely represents manifestations of systemic exposure to fluticasone propionate, as systemic corticosteroids are known to reduce blood eosinophils.
Consistent with the overall study population (10), the incidence of pneumonia was higher with SFC versus IND/GLY, irrespective of blood eosinophil counts. The rate of pneumonia was marginally higher in those with ,2% blood eosinophils than those with >2% blood eosinophils, echoing findings from a post hoc analysis that suggested rates of pneumonia were slightly lower in patients with COPD with higher eosinophil counts and putatively more responsive to ICS (41) .
Conclusions
In our analysis, IND/GLY consistently provided superior benefits over SFC, regardless of blood eosinophil levels. Indeed, there was no cutoff at which SFC was superior to IND/GLY. We believe that at present, blood eosinophils should not be used in patients with COPD to determine who should receive LABA/ICS instead of LABA/LAMA, and that further evidence is required. Whether ICS can provide additional benefits when added to LABA/LAMA, and whether blood eosinophils can be used to predict this benefit, remain to be elucidated. n Author disclosures are available with the text of this article at www.atsjournals.org.
